Missolapola

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA NephropathyMarch 10, 2025- ARO-C3 achieved deep and sustained reductions in alte...

Heb het even nagekeken: op 21/9/20 aangekocht op gemiddeld 4,2 USD en op 7/7/21 verkocht op gemiddeld 25,68 USD. En op 3/1/23 terug aangekocht op 9,64 USD. Nu afwachten hoe de rit zal zijn. Het sen...

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity - ARO-INHBE targets a known pathway that signals the body to store fat in adipose tissue- ...

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD12...

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity- In preclinical studies, investigational ARO-ALK7 silenced Activin rec...

Ben ook aan het wachten op AFMD :-)Heb naast ARWR en AFMD ook nog AVXL in de biotech portefeuille...

NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...

PASADENA, Calif.--(BUSINESS WIRE)--Nov. 26, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT...

Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs- Upon closing, Arrowhead will receive $825 m...

Hier een GAK van $8,79.Fingers crossed!...

x.com/bearbull_trader/status/18596281...‘I went through the updated (14th Nov 2024) institutional holders list of Affimed shares $AFMDWe might be in for a big surprise (ho...

Affimed Reports Third Quarter 2024 Financial Results Business UpdateAFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollm...

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for PlozasiranSeptember 10, 2024PALISADE Phase 3 results demonstrate plozasiran reduced triglycerides by 80% from baseline...

Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical StudiesAugust 14, 2024PDF Version- Company hosting an obesity/metabolic RD ...

Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant CohortIn...

Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung CancerEfficacy and safety of AFM24 in combination with atezolizumab,...

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed HyperlipidemiaMay 29, 2024PDF Version- Zodasiran significantly reduced triglycerides and atherogenic trigl...

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed HyperlipidemiaMay 28, 2024PDF Version- Plozasiran significantly lowered triglyceride levels with commensu...

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinica...

quote:de tuinman schreef op 15 mei 2024 17:55:[...]Ik heb sinds kort Discord. Heb je tips voor me?Geen extra tips, Tuinman.Het wijst zichzelf, gewoon lezen en er het jouw...

We zijn alvast in goed gezelschap met onze visie ;-)...

Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 CongressTreatment with AFM28 innate cell engager (ICE®), ...

Artal Group S.A. Top Holdings and 13F Report (2024)www.marketbeat.com/13f-filings/artal-...Heel interessante info van Discord.Dit fonds, gesticht door de rijkste Belg Eric Wittouck...

Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical OncologyThe preliminary results from the phase 2 study investigating AFM24 in c...

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX® 3-71 in Humanswww.anavex.com/post/anavex-life-scien...

Affimed Announces Sale of Wholly-Owned Subsidiary AbCheckMANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncolo...

finance.yahoo.com/news/anavex-life-sc...Minder goeie start van 2024 voor Anavex …...

Iedereen hier een vruchtbaar beursjaar 2024 gewenst! Voor de investeerders in deze sector kan het toch bijna niet slechter worden dan het in 2023 was.Laat ons hopen dat we dit jaar de heropstanding...

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (B...

Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer PatientsData update from AFM...

Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24Review clinical data of acimtamig in combination with cord-blood derived NK cells presented at ASH ...

Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational ProgressAcimtamig (also known as AFM13) combination with AlloNK® (also known as AB-101): Initiated LuminICE-203. Compa...

Affimed Announces Acimtamig as International Nonproprietary Name for AFM13MANNHEIM, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-st...

quote:de tuinman schreef op 28 oktober 2023 14:54:[...]Waar heb ik dit nog meer gelezen..In tien minuten zes keer een déja-vu ;-)...

Affimed Announces Listing Transfer to Nasdaq Capital MarketsMANNHEIM, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-on...

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1June 27, 2023PASADENA, Calif.--(BUSINESS WIRE)--Jun. 27, 2023-- Arrowhead Pharmaceuticals, Inc. (NAS...

ir.arrowheadpharma.com/news-releases/...Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational...

June 1 (Reuters) - Anavex Life Sciences Corp AVXL.O : * ANAVEX ANNOUNCES ISSUANCE OF NEW U.S. INTELLECTUAL PROPERTY COMPOSITIONS PATENT FOR ANAVEX®2-73 (BLARCAMESINE) * ANAVEX LIFE SCIENCES CORP - PAT...

ir.arrowheadpharma.com/news-releases/...

Ik blijf hier zitten (GAK van $ 0,95) en wacht op een overname/verkoop/partnering.Heb het even nagekeken en op 7/7/2021 heb ik mijn ganse portefeuille met voornamelijk biotech verkocht en het is ont...

Arrowhead Pharmaceuticals Remains A Buy For Pipeline Potential seekingalpha.com/article/4606150-arro...

Bedankt, Piddy!...

Zou er iemand een uitnodigingslink voor Discord ARWR willen plaatsen? Ik geraak er niet meer op. Alvast bedankt!...

Arrowhead delivers in the lung | Evaluatewww.evaluate.com/vantage/articles/int...

Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect | Arrowhead Pharmaceuticals Inc. ir.arrowheadpharm...

www.goingpublic.de/life-sciences/affi...

Truist says Fate’s reboot not a negative for Affimed 7/1/2023 - 00:00 - Reuters ** Brokerage Truist Securities says Fate Therapeutics major business reboot might be a critical point fo...

Eergisteren hier terug ingestapt. En ook bij AVXL.En voor de rest: veel ARWR ;-)...

Meanwhile AMG-890 - now known as Olpasiran - is being rushed into pivotal trials by Amgen after Phase 2 tests revealed a 90% or greater reduction in Lp(A) levels – a biomarker for cardiovascular disea...

ARO-APOC-3 is designed to reduce production of Apolipoprotein C-III - a component of triglyceride rich lipoproteins (TRLs), and its being evaluated in a Phase 3 study in patients with...